Cardiovascular risk factors, burden of disease and preventive strategies in patients with systemic lupus erythematosus: a literature review

Bibliography

• Gatto M, Zen M, Ghirardello A, et al. Emerging and critical issues in the pathogenesis of lupus. Autoimmun Rev 2013;12:523-36
   PubMed Web of Science ®Google Scholar
• Costenbader KH, Gay S, Alarcón-Riquelme ME, et al. Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases? Autoimmun Rev 2012;11:604-9
   PubMed Web of Science ®Google Scholar
• Gladman DD, Urowitz MB, Rahman P, et al. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003;30:1955-9
   PubMed Web of Science ®Google Scholar
• Doria A, Iaccarino L, Ghirardello A, et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med 2006;119:700-6
   PubMed Web of Science ®Google Scholar
• Gustafsson J, Gunnarsson I, Börjesson O, et al. Predictors of the first cardiovascular event in patients with systemic lupus erythematosus: a prospective cohort study. Arthritis Res Ther 2009;11:R186
   PubMed Web of Science ®Google Scholar
• Gustafsson J, Svenungsson E. Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus. Autoimmunity 2014;47:67-76
   PubMed Web of Science ®Google Scholar
• Urowitz MB, Bookman AA, Koehler BE, et al. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976;60:221-5
   PubMed Web of Science ®Google Scholar
• Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the framingham study. Am J Epidemiol 1997;145:408-15
   PubMed Web of Science ®Google Scholar
• Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001;44:2331-7
   PubMed Web of Science ®Google Scholar
• Doria A, Shoenfeld Y, Wu R, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003;62:1071-7
   PubMed Web of Science ®Google Scholar
• Iaccarino L, Bettio S, Zen M, et al. Premature coronary heart disease in SLE: can we prevent progression? Lupus 2013;22:1232-42
   PubMed Web of Science ®Google Scholar
• Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 2010;34:J258-65
   PubMed Web of Science ®Google Scholar
• Costenbader KH, Kim DJ, Peerzada J, et al. Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. Arthritis Rheum 2004;50:849-57
   PubMed Web of Science ®Google Scholar
• Toloza SMA, Uribe AG, McGwin G, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIII. baseline predictors of vascular events. Arthritis Rheum 2004;50:3947-57
   PubMed Web of Science ®Google Scholar
• Parker B1, Urowitz MB, Gladman DD, et al. Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis 2013;72:1308-14
   PubMed Web of Science ®Google Scholar
• Bruce IN, Urowitz MB, Gladman DD, et al. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto risk factor study. Arthritis Rheum 2003;48:3159-67
   PubMed Web of Science ®Google Scholar
• Parker B, Urowitz MB, Gladman DD, et al. Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis 2013;72:1308-14
   PubMed Web of Science ®Google Scholar
• Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399-406
   PubMed Web of Science ®Google Scholar
• McMahon M, Skaggs BJ, Grossman JM, et al. A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheumatol 2014;66:130-9
   PubMed Web of Science ®Google Scholar
• Wilhelm AJ, Major AS. Accelerated atherosclerosis in SLE: mechanisms and prevention approaches. Int J Clin Rheumatol 2012;7:527-39
   PubMedGoogle Scholar
• Shoenfeld Y, Gerli R, Doria A, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005;112:3337-47
   PubMed Web of Science ®Google Scholar
• Bassi N, Ghirardello A, Iaccarino L, et al. OxLDL/β2GPI–anti-oxLDL/β2GPI complex and atherosclerosis in SLE patients. Autoimmun Rev 2007;7:52-8
   PubMed Web of Science ®Google Scholar
• Lazzerini PE, Capecchi PL, Selvi E, et al. Hyperhomocysteinemia: a cardiovascular risk factor in autoimmune diseases? Lupus 2007;16:852-62
   PubMed Web of Science ®Google Scholar
• Scalzi LV, Hollenbeak CS, Wang L. Racial disparities in age at time of cardiovascular events and cardiovascular-related death in patients with systemic lupus erythematosus. Arthritis Rheum 2010;62:2767-75
   PubMed Web of Science ®Google Scholar
• Scalzi LV, Bhatt S, Gilkeson RC, Shaffer ML. The relationship between race, cigarette smoking and carotid intimal medial thickness in systemic lupus erythematosus. Lupus 2009;18:1289-97
   PubMed Web of Science ®Google Scholar
• Szalai AJ, Alarcón GS, Calvo-Alén J, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXX: association between C-reactive protein gene polymorphisms and vascular events. Rheumatology 2005;44:864-8
   PubMed Web of Science ®Google Scholar
• Haque S, Gordon C, Isenberg D, et al. Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study. J Rheumatol 2010;37:322-9
   PubMed Web of Science ®Google Scholar
• Fichtlscherer S, Breuer S, Zeiher AM. Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndromes: further evidence for the existence of the “vulnerable” patient. Circulation 2004;110:1926-32
   PubMed Web of Science ®Google Scholar
• Lee PY, Li Y, Richards HB, et al. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum 2007;56:3759-69
   PubMed Web of Science ®Google Scholar
• Duval A, Helley D, Capron L, et al. Endothelial dysfunction in systemic lupus patients with low disease activity: evaluation by quantification and characterization of circulating endothelial microparticles, role of anti-endothelial cell antibodies. Rheumatology 2010;49:1049-55
   PubMed Web of Science ®Google Scholar
• Rho YH, Chung CP, Oeser A, et al. Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus. J Rheumatol 2008;35:1789-94
   PubMed Web of Science ®Google Scholar
• Mak A, Liu Y, Ho RC. Endothelium-dependent but not endothelium-independent flow-mediated dilation is significantly reduced in patients with systemic lupus erythematosus without vascular events: a metaanalysis and metaregression. J Rheumatol 201l;38:1296-303
   PubMed Web of Science ®Google Scholar
• Reichlin M, Fesmire J, Quintero-Del-Rio AI, Wolfson-Reichlin M. Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum 2002;46:2957-63
   PubMed Web of Science ®Google Scholar
• Bruce IN. ’Not only...but also’: Factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology 2005;44:1492-502
   PubMed Web of Science ®Google Scholar
• Navab M, Anantharamaiah GM, Reddy ST, et al. Mechanisms of disease: proatherogenic HDL—an evolving field. Nat Rev Endocrinol 2006;2:504-11
   Google Scholar
• Lopez LR, Salazar-Paramo M, Palafox-Sanchez C, et al. Oxidized low-density lipoprotein and beta2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness: implications in autoimmune-mediated atherosclerosis. Lupus 2006;15:80-6
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Brilakis ES, Lennon RJ, et al. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J Lipid Res 2007;48:425-33
   PubMed Web of Science ®Google Scholar
• Somers EC, Zhao W, Lewis EE, et al. Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients. PLoS ONE 2012;7:e37000
   Google Scholar
• Thacker SG, Berthier CC, Mattinzoli D, et al. The detrimental effects of IFN-a on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction. J Immunol 2010;185:4457-69
   PubMed Web of Science ®Google Scholar
• Kahlenberg JM, Thacker SG, Berthier CC, et al. Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus. J Immunol 2011;187:6143-56
   PubMed Web of Science ®Google Scholar
• Barnes EV, Narain S, Naranjo A, et al. High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus 2005;14:576-82
   PubMed Web of Science ®Google Scholar
• Goldberg RJ, Urowitz MB, Ibañez D, et al. Risk factors for development of coronary artery disease in women with systemic lupus erythematosus. J Rheumatol 2009;36:2454-61
   PubMed Web of Science ®Google Scholar
• Mor A, Luboshits G, Planer D, et al. Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. Eur Heart J 2006;27:2530-7
   PubMed Web of Science ®Google Scholar
• Klingenberg R, Gerdes N, Badeau RM, et al. Depletion of FOXP3 regulatory T cells promotes hypercholesterolemia and atherosclerosis. J Clin Invest 2013;123:1323-34
   PubMed Web of Science ®Google Scholar
• Doria A, Gatto M. Nephritogenic-antinephritogenic antibody network in lupus glomerulonephritis. Lupus 2012;21:1492-6
   PubMed Web of Science ®Google Scholar
• Rekvig OP, Putterman C, Casu C, et al. Autoantibodies in lupus: culprits or passive bystanders? Autoimmun Rev 2012;11:596-603
   PubMed Web of Science ®Google Scholar
• Magder LS, Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol 2012;176:708-19
   PubMed Web of Science ®Google Scholar
• Petri M. Update on anti-phospholipid antibodies in SLE: the Hopkins’ Lupus Cohort. Lupus 2010;19:419-23
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Kishi M, Atsumi T, et al. Circulating oxidized LDL forms complexes with beta2-glycoprotein I: implication as an atherogenic autoantigen. J Lipid Res 2003;44:716-26
   PubMed Web of Science ®Google Scholar
• Steiman AJ, Gladman DD, Ibañez D, Urowitz MB. Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period. Arthrit Care Res 2012;64:511-18
   PubMed Web of Science ®Google Scholar
• Doria A, Gatto M, Iaccarino L, Punzi L. Value and goals of treat-to-target in systemic lupus erythematosus: knowledge and foresight. Lupus 2015;24:507-15
   PubMed Web of Science ®Google Scholar
• Burgos PI, McGwin G, Reveille JD, et al. Factors predictive of thrombotic events in LUMINA, a multi-ethnic cohort of SLE patients (LXXII). Rheumatology 2010;49:1720-5
   PubMed Web of Science ®Google Scholar
• Alarcòn GS, McGwin G, Bertoli AM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: Data from LUMINA, a multiethnic US cohort LUMINA L). Ann Rheum Dis 2007;66:1168-72
   PubMed Web of Science ®Google Scholar
• Urowitz MB, Gladman DD, Tom BD, et al. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol 2008;35:2152-8
   PubMed Web of Science ®Google Scholar
• Molad Y, Gorshtein A, Wysenbeek AJ, et al. Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an israeli cohort. Lupus 2002;11:356-61
   PubMed Web of Science ®Google Scholar
• Willis R, Seif A, McGwin G, et al. Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort. Lupus 2012;21:830-5
   PubMed Web of Science ®Google Scholar
• Ruiz-Irastorza G, Egurbide M, Pijoan J, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006;15:577-83
   PubMed Web of Science ®Google Scholar
• Jung H, Bobba R, Su J, et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 2010;62:863-8
   PubMed Web of Science ®Google Scholar
• Tam L, Gladman D, Hallett D, et al. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 2000;27:2142-5
   PubMed Web of Science ®Google Scholar
• Oryoji K, Kiyohara C, Horiuchi T, et al. Reduced carotid intima-media thickness in systemic lupus erythematosus patients treated with cyclosporine A. Mod Rheumatol 2014;24:86-92
   PubMed Web of Science ®Google Scholar
• Sazliyana S, Mohd Shahrir MS, Kong CT, et al. Implications of immunosuppressive agents in cardiovascular risks and carotid intima media thickness among lupus nephritis patients. Lupus 2011;20:1260-6
   PubMed Web of Science ®Google Scholar
• Kisiel B, Kruszewski R, Juszkiewicz A, et al. Methotrexate, Cyclosporine A, and Biologics Protect against Atherosclerosis in Rheumatoid Arthritis. J Immunol Res 2015;2015:759610
   PubMed Web of Science ®Google Scholar
• Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011;108:1362-70
   PubMed Web of Science ®Google Scholar
• Romero F, Rodriguez-Iturbe B, Pons H, et al. Mycophenolate mofetil reduces cholesterol-induced atherosclerosis in the rabbit. Atherosclerosis 2000;152:127-33
   PubMed Web of Science ®Google Scholar
• van Leuven SI, Mendez-Fernandez YV, Wilhelm AJ, et al. Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr(-/-) mice. Ann Rheum Dis 2012;71:408-14
   PubMed Web of Science ®Google Scholar
• Kobashigawa JA, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998;66:507-15
   PubMed Web of Science ®Google Scholar
• Kiani AN, Madger LS, Petri M. Mycophenolate mofetil (MMF) does not slow the progression of subclinical atherosclerosis in SLE over 2 years. Rheumatol Int 2012;32:2701-5
   PubMed Web of Science ®Google Scholar
• Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2002;2:807-18
   PubMed Web of Science ®Google Scholar
• Schanberg LE, Sandborg C, Barnhart HX, et al. Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators. Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. Arthritis Rheum 2009;60:1496-507
   PubMed Web of Science ®Google Scholar
• Ahmad Y, Bodill H, Shelmerdine J, et al. Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and the lupus phenotype. Rheumatology 2007;46:983-8
   PubMed Web of Science ®Google Scholar
• Zanoli L, Rastelli S, Inserra G, et al. Increased arterial stiffness in inflammatory bowel diseases is dependent upon inflammation and reduced by immunomodulatory drugs. Atherosclerosis 2014;234:346-51
   PubMed Web of Science ®Google Scholar
• Selzer F, Sutton-Tyrrell K, Fitzgerald SG, et al. Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum 2004;50:151-9
   PubMed Web of Science ®Google Scholar
• Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62:222-33
   PubMed Web of Science ®Google Scholar
• Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64:1215-26
   PubMed Web of Science ®Google Scholar
• Iaccarino L, Bartoloni E, Carli L, et al. Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. Clin Exp Rheumatol 2015. [Epub ahead of print]
   Google Scholar
• Pego-Reigosa JM, Lu TY, Fontanillo MF, et al. Long-term improvement of lipid profile in patients with refractory systemic lupus erythematosus treated with B-cell depletion therapy: a retrospective observational study. Rheumatology 2010;49:691-6
   PubMed Web of Science ®Google Scholar
• Gatto M, Kiss E, Naparstek Y, Doria A. In-/off-label use of biologic therapy in systemic lupus erythematosus. BMC Med 2014;12:30
   PubMed Web of Science ®Google Scholar
• Kyaw T, Tay C, Hosseini H, et al. Depletion of B2 but Not B1a B cells in BAFF receptor- deficient ApoE −/− mice attenuates atherosclerosis by potently ameliorating arterial inflammation. Atherosclerosis 2012;7:1-10
   Google Scholar
• Costenbader KH, Karlson EW, Gall V, et al. Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus. Arthritis Rheum 2005;53:718-23
   PubMed Web of Science ®Google Scholar
• Eriksson K, Svenungsson E, Karreskog H, et al. Physical activity in patients with systemic lupus erythematosus and matched controls. Scand J Rheumatol 2012;41:290-7
   PubMed Web of Science ®Google Scholar
• Dyerberg J, Bang H, Stoffersen E, et al. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet 1978;312:117-19
   Google Scholar
• Im DS. Omega-3 fatty acids in anti-inflammation (pro-resolution) and GPCRs. Prog Lipid Res 2012;51:232-7
   PubMed Web of Science ®Google Scholar
• Spite M, Norling LV, Summers L, et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 2009;461:1287-91
   PubMed Web of Science ®Google Scholar
• Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090-8
   PubMed Web of Science ®Google Scholar
• Wright SA, O’Prey FM, McHenry MT, et al. A randomised interventional trial of ω-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus. Ann Rheum Dis 2008;67:841-8
   PubMed Web of Science ®Google Scholar
• Remans P, Sont J, Wagenaar L, et al. Nutrient supplementation with polyunsaturated fatty acids and micronutrients in rheumatoid arthritis: clinical and biochemical effects. Eur J Clin Nutr 2004;58:839-45
   PubMed Web of Science ®Google Scholar
• Geldmeyer-Hilt K, Heine G, Hartmann B, et al. 1, 25-dihydroxyvitamin D 3 impairs NF-κB activation in human naïve B cells. Biochem Bioph Res Co 2011;407:699-702
   PubMed Web of Science ®Google Scholar
• Amital H, Szekanecz Z, Szücs G, et al. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D? Ann Rheum Dis 2010;69:1155-7
   PubMed Web of Science ®Google Scholar
• Poole KES, Loveridge N, Barker PJ, et al. Reduced vitamin D in acute stroke. Stroke 2006;37:243-5
   PubMed Web of Science ®Google Scholar
• Ravenell RL, Kamen DL, Spence JD, et al. Premature atherosclerosis is associated with hypovitaminosis D and angiotensin-converting enzyme inhibitor non-use in lupus patients. Am J Med Sci 2012;344:268-73
   PubMed Web of Science ®Google Scholar
• Reynolds JA, Haque S, Berry JL, et al. 25-hydroxyvitamin D deficiency is associated with increased aortic stiffness in patients with systemic lupus erythematosus. Rheumatology 2012;51:544-51
   PubMed Web of Science ®Google Scholar
• George PS, Pearson ER, Witham MD. Effect of vitamin D supplementation on glycaemic control and insulin resistance: a systematic review and meta-analysis. Diabetic Med 2012;29:e142-50
   PubMed Web of Science ®Google Scholar
• Wang ZX, Wang CQ, Li XY, et al. Changes of naturally occurring CD4(+)CD25(+) FOXP3(+) regulatory T cells in patients with acute coronary syndrome and the beneficial effects of atorvastatin treatment. Int Heart J 2015;56:163-9
   PubMed Web of Science ®Google Scholar
• Plazak W, Gryga K, Dziedzic H, et al. Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study. Arthritis Res Ther 2011;13:R117
   PubMed Web of Science ®Google Scholar
• Mok CC, Wong CK, To CH, et al. Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: a randomized, double-blind, placebo-controlled trial. Arthritis Care Res 2011;63:875-83
   PubMed Web of Science ®Google Scholar
• Tang TT, Song Y, Ding YJ, et al. Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis. J Lipid Res 2011;52:1023-32
   PubMed Web of Science ®Google Scholar
• Petri MA, Kiani AN, Post W, et al. Lupus atherosclerosis prevention study (LAPS). Ann Rheum 2011;70:760-5
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 2014;73:958-67
   PubMed Web of Science ®Google Scholar